39 resultados para Deauville (Calvados)


Relevância:

10.00% 10.00%

Publicador:

Resumo:

Référence bibliographique : Rol, 55608

Relevância:

10.00% 10.00%

Publicador:

Resumo:

PURPOSE Our main objective was to prospectively determine the prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) after two cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone given every 14 days (R-CHOP-14) under standardized treatment and PET evaluation criteria. PATIENTS AND METHODS Patients with any stage of diffuse large B-cell lymphoma were treated with six cycles of R-CHOP-14 followed by two cycles of rituximab. PET/CT examinations were performed at baseline, after two cycles (and after four cycles if the patient was PET-positive after two cycles), and at the end of treatment. PET/CT examinations were evaluated locally and by central review. The primary end point was event-free survival at 2 years (2-year EFS). RESULTS Median age of the 138 evaluable patients was 58.5 years with a WHO performance status of 0, 1, or 2 in 56%, 36%, or 8% of the patients, respectively. By local assessment, 83 PET/CT scans (60%) were reported as positive and 55 (40%) as negative after two cycles of R-CHOP-14. Two-year EFS was significantly shorter for PET-positive compared with PET-negative patients (48% v 74%; P = .004). Overall survival at 2 years was not significantly different, with 88% for PET-positive versus 91% for PET-negative patients (P = .46). By using central review and the Deauville criteria, 2-year EFS was 41% versus 76% (P < .001) for patients who had interim PET/CT scans after two cycles of R-CHOP-14 and 24% versus 72% (P < .001) for patients who had PET/CT scans at the end of treatment. CONCLUSION Our results confirmed that an interim PET/CT scan has limited prognostic value in patients with diffuse large B-cell lymphoma homogeneously treated with six cycles of R-CHOP-14 in a large prospective trial. At this point, interim PET/CT scanning is not ready for clinical use to guide treatment decisions in individual patients.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Signatur des Originals: S 36/G04586

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Introductory chapter of each volume signed: Onésime Reclus.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Publication suspended from 1873 to 1891.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Plates numbered irregularly.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Mémoire couronné, le 8 décembre 1836, par la Société philharmonique du Calvados.